Atrophic ScarNCT07892937
CIC101-02-LT is a Long-term Follow-up Study of Subjects Treated With TRTP-101 and Will Evaluate the Long-term Safety and Efficacy of TRTP-101.
An observational study of Atrophic Scar, run by CellinCells.
Trial summary
CIC101-02-LT is a long-term follow-up study of subjects treated with TRTP-101 and will evaluate the long-term safety and efficacy of TRTP-101. Read more about this study
- Who is it for?
- Ages 19 years and olderHealthy volunteers can take part
- Conditions the study is for
- Atrophic Scar
- How many people
- 31 participants
- Where
- No sites listed yet
- Study dates
- 31 Mar 2027to 31 Dec 2033
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults with Atrophic Scars Treated with TRTP-101 in Study CIC101-02
Who may be able to join
- Received TRTP-101 in clinical trial CIC101-02
- Provided written informed consent to participate in this study
Who cannot join
- Judged to face significant health or safety risks by participating in this long-term follow-up study
- Judged to be unable to continuously participate in or complete this long-term follow-up study
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Long-Term Follow-up of Adults With Atrophic Scars Treated With TRTP-101 in Study CIC101-02
CIC101-02-LT is a long-term follow-up study of subjects treated with TRTP-101 and will evaluate the long-term safety and efficacy of TRTP-101.
Read the detailed description
The long-term safety of TRTP-101 was evaluated by participants in clinical trial CIC101-02 and followed up for 5 years for serious adverse events.
- Conditions
- Atrophic Scar
What is being measured
The primary outcome is the main question the study is designed to answer.
Serious Adverse Event
SAE will be collected
Measured: Up to 5 years
Secondary outcomes (1)
Mean percent change in atrophic scar volume
The depressed volume of atropic scar is measured at baseline in study CIC101-02
Measured: 6 (only Phase 1 participants), 12, 18 and 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2026
- Study start31 Mar 2027 (estimated)
- Primary completion31 Mar 2033 (estimated)
- Study completion31 Dec 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrophic ScarStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 31 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CellinCells
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- JongHee Lee, MD, Principal investigator, Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07892937
- Sponsor's protocol ID
- CIC101-02-LT
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-Term Follow-up of Adults With Atrophic Scars Treated With TRTP-101 in Study CIC101-02
- ClinicalTrials.gov ID
- NCT07892937
- Acronym / sponsor ID
- CIC101-02-LT
- Conditions
- Atrophic Scar
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 31 participants (estimated)
- Lead sponsor
- CellinCellsIndustry (pharma, biotech, devices)
- Study start
- 31 Mar 2027 (estimated)
- Primary completion
- 31 Mar 2033 (estimated)
- Study completion
- 31 Dec 2033 (estimated)
- First posted
- 23 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CIC101-02-LT is a long-term follow-up study of subjects treated with TRTP-101 and will evaluate the long-term safety and efficacy of TRTP-101.
Detailed description
The long-term safety of TRTP-101 was evaluated by participants in clinical trial CIC101-02 and followed up for 5 years for serious adverse events.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with Atrophic Scars Treated with TRTP-101 in Study CIC101-02
Key inclusion criteria (2 listed)
- Received TRTP-101 in clinical trial CIC101-02
- Provided written informed consent to participate in this study
Key exclusion criteria (2 listed)
- Judged to face significant health or safety risks by participating in this long-term follow-up study
- Judged to be unable to continuously participate in or complete this long-term follow-up study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Serious Adverse Event
Time frame: Up to 5 years
SAE will be collected
1 secondary outcome
Mean percent change in atrophic scar volume
Time frame: 6 (only Phase 1 participants), 12, 18 and 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
Related trials for Atrophic Scar
Recruiting
Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation
Recruiting
AVAVA MIRIA General Use
Acne, Acne Scars - Mixed Atrophic and Hypertrophic
RecruitingPhase 1/2
Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars
Atrophic Scar
Enrolling by invitation
Nanofat Injection and Fractional CO2 Laser for Post-Traumatic Atrophic Scars
Post-Traumatic Atrophic Scar, Atrophic Scar
Not yet recruiting
Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars
Acne Scars, Acne Scars - Atrophic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
JongHee Lee, MD principal investigator
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine
Questions about this trial
What is this clinical trial studying?
An observational study of Atrophic Scar, run by CellinCells.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact HyeJung Park, Director (82-70-4469-9115, hjpark@cellincells.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serious Adverse Event (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.